
    
      This is an open-label (all people know the identity of the intervention), study to evaluate
      the pharmacokinetics, safety and antiviral activity. Approximately 24 HIV-1 infected children
      will be enrolled in this study. The study consists of a 4-week screening period, a 48-week
      treatment period, and a 4-week follow-up period. Participants will receive DRV/rtv according
      to their body weight. Safety evaluations will include assessment of adverse events,
      laboratory tests, physical Examination, neurologic examination, vital signs, and
      electrocardiogram. The total duration of the study will be 56 weeks.
    
  